Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC28-E vs Aflibercept in Wet Age-Related Macular Degeneration
NCT05727397Phase 3Recruiting
- Sponsor
- RemeGen
- Start
- Mar 2023
- Primary completion
- Nov 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of eflimrufusp alfa in exudative macular degeneration, sponsored by RemeGen. Started Mar 2023; status: recruiting.
02
Drugs
eflimrufusp alfa
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT05727397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727397.